BIOFILCHEM vs GLAXO: Stock Comparison
Biofil Chemicals & Pharmaceuticals Limited vs GlaxoSmithKline Pharmaceuticals Limited
Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings
GlaxoSmithKline Pharmaceuticals Limited is the larger company by market capitalisation. GlaxoSmithKline Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and GlaxoSmithKline Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| Live Price | ₹32.07 | ₹2,514.3 |
| Day Change | -1.14% | 0.77% |
| Volume | 4,169 | 63,793 |
| 52-Week High | ₹46.34 | ₹3,220 |
| 52-Week Low | ₹25.6 | ₹2,088.1 |
| Distance from 52W High | -30.79% | -21.92% |
Valuation
| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| Market Cap | ₹52 Cr | ₹42,548 Cr |
| P/E Ratio | — | 41.15x |
| P/B Ratio | — | 18.8x |
| EPS | ₹1.71 | ₹62.29 |
| Book Value | ₹13.21 | ₹133.85 |
| Dividend Yield | 0% | 2.27% |
Growth
| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| Revenue Growth (TTM YoY) | -9.3% | 2.1% |
| EPS Growth (TTM YoY) | 10.8% | 5.7% |
| Qtr Sales Growth | -9.34% | 2.15% |
| Qtr Profit Growth | 5% | 5.7% |
Profitability & Leverage
| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| ROE | 13.8% | 45.6% |
| ROCE | 15.8% | 61.4% |
| Net Margin | 9.81% | 27.29% |
| Operating Margin | 2.29% | 34.3% |
| Debt to Equity | 0.14x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BIOFILCHEM | GLAXO |
|---|---|---|
| Promoter Holding | 46.79% | 75% |
| FII Holding | 0% | 4.79%▲ 0.17 pp |
| DII Holding | 0.08% | 7.8%▲ 0.12 pp |
| Public Holding | 53.13% | 12.41%▼ 0.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and GlaxoSmithKline Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.